One-third of adults with an intellectual or developmental disability are dispensed antipsychotics, despite having no existing psychiatric diagnosis.
Large cohort study demonstrates that those with an intellectual disability are at an increased risk for movement disorder side effects of antipsychotics.
20-year follow-up study finds that after four years, patients not prescribed antipsychotics have significantly better work functioning.
A large review and meta-analysis of 167 studies across 60 years dissects placebo-controlled randomized controlled trials of antipsychotic drugs.
No placebo controlled trials provide evidence of antipsychotics in first-episode psychosis.
A large longitudinal study finds once more that being prescribed antipsychotics significantly increases the risk of diabetes.
A large observational study published in CNS Drugs sheds light on serious adverse effects of the ‘gold standard’ antipsychotic Clozapine.
Jeffrey LIeberman and colleagues have published a paper in the American Journal of Psychiatry stating that there is no evidence that psychiatric drugs cause long-term harm, and that the evidence shows that these drugs provide a great benefit to patients. A close examination of their review reveals that it is a classic example of institutional corruption, which was meant to protect guild interests.
Reduced usage of antipsychotics in first-episode psychosis was associated with improved executive functioning.
Study finds that 74% of patients with a psychotic disorder off antipsychotics at end of 10 years are in remission.
Researchers recommend that healthcare professionals be vigilant regarding the signs of respiratory failure among patients with COPD who are receiving antipsychotics, especially during the initial treatment phase.
Researchers believe that side-effect monitoring is critical because of the increase in the use of antipsychotics
A review of the scientific literature related to the withdrawal of antipsychotics: animal studies, withdrawal symptoms, tapering success rates, and consumer accounts of discontinuation.
Association found between long-term antipsychotic use and poorer performance on cognitive tasks in adults diagnosed with ‘schizophrenia.’
Patients who recover from a single episode of psychosis are often prescribed antipsychotics long-term, despite a lack of evidence for this practice
The researchers find that the drug effects for reducing psychosis are small and that treatment failure and severe side effects are common.
This guide, by psychiatrists Volkmar Aderhold and Peter Stastny, provides a comprehensive review of antipsychotics and an evidence-based rationale for avoiding their use in first-episode psychosis, and for minimizing their long-term use.
Long-term treatment with antipsychotic drugs is currently considered the standard treatment for patients diagnosed with ‘schizophrenia.’ A new study challenges this practice, however. The...
This review of the scientific literature, stretching across six decades, makes the case that antipsychotics, over the long-term, do more harm than good. The drugs lower recovery rates and worsen functional outcomes over longer periods of time.
A new study published this month in the journal Neuron identifies the mechanism by which antipsychotic drugs can induce parkinsonism, a condition involving movement...
A systematic review published this week in the British Journal of Clinical Pharmacology found that patients taking antipsychotic drugs were at nearly twice the risk...
The US FDA has issued a new warning for the atypical antipsychotic Olanzapine, also known by the brand names Zyprexa and Symbyax. The agency...
Yesterday, the US Food and Drug Administration (FDA) released a warning that the antipsychotic drug aripiprazole or Abilify is associated with compulsive and uncontrollable...
A new study in JAMA Neurology finds that the use of antipsychotic drugs more than doubled the risk of death in patients with Parkinson’s...
In a study published yesterday, researchers from the Nippon Medical School in Tokyo bring attention to a condition known as neuroleptic-induced deficit syndrome (NIDS)...